Biblio
2020
Borlenghi E, Cattaneo C, Cerqui E, Archetti S, Bertoli D, Bellotti D, Gramegna D, Soverini G, Oberti M, Schieppati F, et al. Post-remission Therapy with Repeated Courses of High Dose Cytarabine, Idarubicin and Limited Autologous Stem Cell Support Achieves a Very Good Long-Term Outcome in ELN Favorable and Intermediate-Risk AML. Hematol Oncol. 2020.